eravacycline

has antibacterial activity

Also Known As:

(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide dihydrochloride; 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline; MMV1578574; TP-434; TP-434-046; TP-434046; TP434; Xerava; eravacycline dihydrochloride

Networked: 102 relevant articles (11 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bassetti, Matteo: 8 articles (09/2022 - 11/2014)
2.	Nicolau, David P: 6 articles (12/2020 - 01/2014)
3.	Sutcliffe, Joyce A: 6 articles (01/2018 - 01/2012)
4.	Hsueh, Po-Ren: 5 articles (10/2022 - 01/2019)
5.	Izmailyan, Sergey: 5 articles (06/2021 - 11/2018)
6.	Tsai, Larry: 5 articles (10/2019 - 01/2017)
7.	Lee, Wen-Sen: 4 articles (10/2022 - 05/2019)
8.	Olesky, Melanie: 4 articles (01/2020 - 01/2018)
9.	Grossman, Trudy H: 4 articles (01/2018 - 01/2012)
10.	Chen, Yen-Hsu: 3 articles (10/2022 - 01/2019)

Related Diseases

1.	Infections 12/01/2020 - "In this real-world setting, eravacycline demonstrated a similar high level of clinical efficacy as seen in clinical trials, 94%, in a variety of infections, including against multidrug-resistant bacteria, and was well tolerated." 05/01/2018 - "This study aimed to assess the correlation of the PK/PD index fAUC/MIC (ratio of area under the free drug concentration-time curve to MIC) and its magnitude with eravacycline's efficacy against Enterobacteriaceae using an immunocompetent murine thigh infection model to resemble the immunocompetent environment in eravacycline's clinical trials. " 01/01/2017 - "In subsequent studies, we used the neutropenic murine thigh infection model to determine if the magnitude of the AUC/MIC needed for the efficacy of eravacycline varied among pathogens. " 01/01/2022 - "Nevertheless, 95.5% experienced clinical improvement, with 86.4% achieving full infection resolution following eravacycline. " 01/01/2020 - "This study further underscores the potential benefit of eravacycline in the treatment of infections caused by MDR Gram-negative pathogens."
2.	Intraabdominal Infections 10/01/2019 - "Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance." 06/01/2021 - "Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies." 01/01/2021 - "This study was conducted to evaluate the efficacy and safety of eravacycline, a recently approved fluorocycline for treatment of complicated intra-abdominal infections (cIAIs). " 06/17/2019 - "This study aims to assess the clinical efficacy and safety of eravacycline for treating complicated intra-abdominal infection (cIAI) in adult patients. " 06/17/2019 - "The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials."
3.	Malaria 12/01/2022 - "Erratum to 'In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite Plasmodium falciparum' [Journal of Global Antimicrobial Resistance 24 (2021) 93-97]." 01/01/2021 - "In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite Plasmodium falciparum." 10/01/2023 - "[Investigation of the Efficacy of Cinnamaldehyde, Cannabidiol and Eravacycline in a Malaria Model]." 10/01/2023 - "In this study, it was aimed to investigate the antimalarial activity of cinnamaldehyde (CIN) and cannabidiol (CBD) which have shown various biological activities such as potent antimicrobial activity and eravacycline (ERA), a new generation tetracycline derivative, in an in vivo malaria model. "
4.	Pyelonephritis 04/01/2016 - "Several animal model studies including mouse systemic infection, thigh infection, lung infection, and pyelonephritis models have been published and demonstrated the in vivo efficacy of eravacycline. "
5.	Nausea 12/01/2020 - "The drug was well tolerated with only two reports of nausea, which did not result in treatment discontinuation, and in 30 days of post-eravacycline therapy only one case of Clostridiodes difficile. " 01/01/2021 - "Eravacycline was associated with significantly greater odds of total AEs (OR, 1.55, 95% CI 1.20-1.99; I2 = 0%) and nausea (OR, 5.29, 95% CI 1.77-15.78; I2 = 1.70%) but the increase in vomiting was non-significant (OR, 1.44, 95% CI 0.73-2.86; I2 = 1.70%). " 01/01/2022 - "Adverse events were uncommon (4.5%), limited to nausea/vomiting, and not leading to eravacycline discontinuation. " 01/01/2021 - "However, the odds of total AEs and specifically nausea was higher with eravacycline, while no significant differences were observed in vomiting (although numerically higher), serious AEs or discontinuation due to AEs." 11/01/2018 - "Eravacycline was generally well tolerated, with dose-related nausea, infusion site effects, and superficial phlebitis that were mild or moderate occurring. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	omadacycline
3.	Cannabidiol
4.	cinnamaldehyde (cinnamic aldehyde)
5.	Tigecycline (Tygacil)
6.	Meropenem (Merrem)
7.	Ertapenem (Invanz)
8.	Tetracycline (Achromycin)
9.	Cefiderocol
10.	plazomicin

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Salvage Therapy
4.	Extracorporeal Membrane Oxygenation